Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Xenova Group plc (XEN)

  Print      Mail a friend

Monday 07 June, 2004

Xenova Group plc

Product Update

Xenova Group plc

Tariquidar Phase I Paediatric Study
Data Presented at ASCO

Abstract on XR5944 also presented

Slough, UK, 7 June 2004 - Xenova Group plc (London Stock Exchange:
XEN; NASDAQ: XNVA) announced today that the Paediatric Oncology
Branch of the National Cancer Institute (NCI) in Bethesda, US,
yesterday presented a poster at the American Society of Clinical
Oncology (ASCO) conference in New Orleans, Louisiana on the
paediatric Phase I clinical trial of tariquidar in children with
solid tumours.

The primary objectives of this trial were to assess the toxicity,
optimal dose and pharmacokinetics of tariquidar in children with
solid tumours and to assess the toxicity and pharmacokinetics of the
anti cancer drugs in combination with tariquidar.  A total of 18
children have been enrolled into the study to date, between the ages
of 2 and 18 with a range of tumours including Ewing's Sarcoma,
osteosarcoma and adrenocortical carcinoma amongst others.

Tariquidar was administered intravenously over 30 minutes with a
starting dose of 1mg/kg in four patients and then escalated to
1.5mg/kg in six patients and then to 2.0mg/kg in the eight remaining
patients.  This was followed by administration of the anti-cancer
drug which was chosen on the basis of tumour type and prior therapy.
Doxorubicin was administered to 11 patients at 50mg/m2, docetaxel was
administered to four patients at 75mg/m2 and vinorelbine was
administered to two patients at 20mg/m2 on days one and eight.
Fligrastim was administered to all patients during the 21 day cycle.

The results of the study showed that tariquidar was well tolerated in
children.  Of the 18 subjects enrolled, one patient had a complete
response, one had a partial response and five had stable disease for
one to eight cycles of therapy.  Doxorubicin clearance was comparable
to previously published results indicating the clearance of
doxorubicin was not altered by pre-treatment with tariquidar. The
future development of tariquidar by Xenova is currently under review.

Commenting on these results, David Oxlade, Chief Executive Officer of
Xenova, said, "It is encouraging to see these results in children
with solid tumours.  The NCI is undertaking a number of exploratory
clinical trials with tariquidar in both adults and children and we
look forward to further results from these studies."

In addition to this poster, Xenova and Millennium have an abstract
published relating to the on-going Phase I study of XR5944 at the
same meeting.


Xenova Group plc +44 (0)1753 706600
David A. Oxlade, Chief Executive Officer
Daniel Abrams, Finance Director
Veronica Cefis Sellar, Head of Corporate Communications

UK - Financial Dynamics +44 (0)20 7831 3113
David Yates
Ben Atwell

US - Trout Group/BMC Communications +1 212 477 9007
Media: Brad Miles
Investors: Lee Stern

Xenova Group plc is a UK-based biopharmaceutical company focused on
the development of novel drugs to treat cancer and addiction with a
secondary focus in immunotherapy. The Company has a broad pipeline of
products in clinical development, including three cancer programmes:
its lead product TransMID(TM), for the treatment of high-grade
glioma, is in Phase III trials, and its novel DNA targeting agents
and XR303 are both in Phase I for cancer indications. Xenova is also
developing two therapeutic vaccines for cocaine and nicotine
addiction, which are in Phase II and Phase I trials respectively.
Quoted on the London Stock Exchange (XEN) and on NASDAQ (XNVA),
Xenova employs approximately 112 people throughout its sites in the
UK and North America. (Reuters XEN.L; Bloomberg XEN LN)
For further information about Xenova and its products please visit
the Xenova website at

For Xenova: Disclaimer to take advantage of the "Safe Harbor"
provisions of the US Private Securities Litigation Reform Act of
1995. This press release contains "forward-looking statements,"
including statements about development and commercialization of
products. Various risks may cause Xenova's actual results to differ
materially from those expressed or implied by the forward looking
statements, including: unexpected costs and delays, adverse results
in our drug discovery and clinical development programs; failure to
obtain patent protection for our discoveries; commercial limitations
imposed by patents owned or controlled by third parties; our
dependence upon strategic alliance partners to develop and
commercialize products and services; difficulties or delays in
obtaining regulatory approvals to market products and services
resulting from our development efforts; the requirement for
substantial funding to conduct research and development and to expand
commercialization activities; and product initiatives by competitors.
For a further list and description of the risks and uncertainties we
face, see the reports we have filed with the Securities and Exchange
Commission. We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.